Weighted average monthly Medicare Advantage (MA) premiums are projected to fall 16.5% in 2027, while average premiums for ...
Open-source oncology tools span patient-facing trackers and explainers, genomics-to-therapy ranking systems, and LLMs ...
Before defining a network meta-analysis, Dr. Citrome walks through the statistical fundamentals that make one useful. He ...
Specialty pharmacy workflows—access, education, interaction checks, toxicity management—mitigate BTK antiplatelet risks and ...
Weekly cataplexy rates fell ~79%–89% with oveporexton versus ~28%–39% with placebo, increasing cataplexy-free days from 0 to ~3.8–5.1 weekly. Treatment-emergent adverse events were common (86%–89% vs ...
The “Washington Ways Without Means” session was moderated by Nick Ferreyros, managing director of policy, advocacy, and ...
Drug acquisition costs are trackable, but operational inputs—training time, monitoring intensity, site activation, and ...
Incremental outcomes favored tirzepatide (4.46 QALYs; $190,270) and semaglutide (3.04 QALYs; $243,094) versus resmetirom (3.47 QALYs; $948,743), driving large ICER separation.
Mayo Clinic's Scott Soefje, PharmD, MBA, explains how logistics, contracts, and cost shape access to new cancer drugs and ...
Grace Mackleby, PhD, explores why dually eligible beneficiaries more often switch MA plans than leave for traditional ...
Symptom tracking can recalibrate perceptions of “normal” menstruation, increase self-management behaviors, and prompt ...
Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results